Nitric oxide, angiotensin II, and hypertension

Ming Sheng Zhou, Ivonne H. Schulman, Leopoldo Raij

Research output: Contribution to journalArticlepeer-review

87 Scopus citations


Although initially adaptive, the changes that accompany hypertension, namely, cell growth, endothelial dysfunction, and extracellular matrix deposition, eventually can become maladaptive and lead to end-organ disease such as heart failure, coronary artery disease, and renal failure. A functional imbalance between angiotensin II (Ang II) and nitric oxide (NO) plays an important pathogenetic role in hypertensive end-organ injury. NO, an endogenous vasodilator, inhibitor of vascular smooth muscle and mesangial cell growth, and natriuretic agent, is synthesized in the endothelium by a constitutive NO synthase. NO antagonizes the effects of Ang II on vascular tone, cell growth, and renal sodium excretion, and also down-regulates the synthesis of angiotensin-converting enzyme (ACE) and Ang II type 1 receptors. On the other hand, Ang II decreases NO bioavailability by promoting oxidative stress. A better understanding of the pathophysiologic mechanisms involved in hypertensive end-organ damage may aid in identifying markers of cardiovascular susceptibility to injury and in developing therapeutic interventions. We propose that those antihypertensive agents that lower blood pressure and concomitantly restore the homeostatic balance of vasoactive agents such as Ang II and NO within the vessel wall would be more effective in preventing or arresting end-organ disease.

Original languageEnglish (US)
Pages (from-to)366-378
Number of pages13
JournalSeminars in Nephrology
Issue number4
StatePublished - Jul 2004

ASJC Scopus subject areas

  • Nephrology


Dive into the research topics of 'Nitric oxide, angiotensin II, and hypertension'. Together they form a unique fingerprint.

Cite this